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Conclusion: Stereotactic reirradiation with CyberKnife for 
recurrent brain metastases, seems to be a safe and effective 
approach in selected patients. However, in the absence of 
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Purpose or Objective: Thalamic tumours represent 5.2% of 
all intracranial tumours and are typically diagnosed in the 
paediatric population. These tumors arise from glial cells 
with an aggressive behavior and a high grade histology. They 
have a poor prognosis. The aim of this study was to find new 
approaches for defining the clinical target volume for these 
tumors. 
 
Material and Methods: Clinical data were collected form 
archived files of 30 patients diagnosed with thalamic gliomas 
based on pathologic and radiologic criteria. 
 
Results: Three patterns of tumor spread were found. The 
first pattern followed the thalamic tributaries of the 
posterior part of the internal cerebral veins. These were the 
anterior and superior thalamic veins. For the second pattern 
the close proximity of the internal cerebral vein branches of 
the superior thalamic veins was a potential route of spread 
between the medial surfaces of the thalami. In addition to 
spread across the midline tumours could also spread along 
the adjacent tectal, pineal and/or vermian veins. The third 
pattern of thalamic tumor spread was found in gliomas which 
use the anterior tributaries of the internal cerebral venous 
architecture of the posterior and inferior branches from the 
basal vein of Rosenthal. 
 
Conclusion: Thalamic gliomas spread upon the peritumoral 
architecture of the perivenous/subglial Scherer structures 
and this knowledge should be used for redefining the clinical 
target volume for radiation therapy in thalamic gliomas 
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Purpose or Objective; Evidence for the use of stereotactic 
radiosurgery (SRS) to 1-3 brain metastases (BM) can be 
derived from historic prospective trials. With improvements 
in the ability to control systemic disease, better access to 
SRS and concerns with WBRT associated neurocognitive 
toxicity many institutions now offer SRS to patients with 
greater than 3 metastases. The purpose of this study was to 
review local control and survival outcomes of patients with 4 
or more BM treated with SRS. 
 
Material and Methods: Patients with BM treated with SRS for 
4 or more lesions between June 2011 and April 2015 were 
identified from a prospective database. Patients were 
deemed suitable for SRS if they had preserved Karnofsky 
performance status (> 70), controllable systemic disease and 
an estimated prognosis of > 6 months with a total intracranial 
metastatic volume of < 20 cm3. Local control and overall 
survival rates were estimated using Kaplan Meier curves. 
 
Results: A total of 16 patients (median age 54 years) with 85 
lesions were treated with primary pathology as follows: 
breast 3 (18.6%); lung 5 (31.3%); melanoma 6 (31.3%) and 
others 2 (12.5%). Median number of lesions treated was 5, 
with median total volume of BM per patient of 1.63cm3. 
Minimum follow up post SRS in all patients was 6 months. Six 
(37.5%) patients had received previous WBRT. Eight patients 
(50%) experienced distant intracranial relapse, 6 (75%) of 
whom had not received prior WBRT. Of these 6 patients; 3 
(50%) received salvage WBRT, 2 (33.3%) were suitable for 
further SRS and 1 (16.7%) refused further intervention. Of the 
10 patients who had not received WBRT prior to SRS, 6 had 
confirmed distant relapse. The median whole brain 
radiotherapy free survival (i.e. time from initial SRS to either 
salvage WBRT or death) was 6.1 months. Eleven lesions 
(12.9%) recurred locally after a median of 226 days (range 85 
– 235) post SRS. Median overall survival was 8.3 months 
(range 21 – 548). 
 
Conclusion: The median survival in this series suggests there 
may be a group of patients with greater than 3 metastases 
that could benefit from SRS. Although patient numbers are 
small, this data may suggest that durable whole brain free 
survival (an important quality of life outcome) may be 
achievable in patients initially treated with SRS only. 
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Purpose or Objective: The primary objective of the study is 
to assess the survival and quality of life after re-irradiation of 
relapsing malignant brain tumors. The second objective was 
to evaluate the influence of some prognostic factors on 
survival.  
 
Material and Methods: Fifteen patients received radiation 
re-treatment for relapse in primary brain tumor between 
October 2011 and May 2015. The interval between two 
consecutive treatments was at least 1 year. Treatment was 
carried out with Conformal Radiotherapy (3D-CRT). The total 
dose radiation of the first treatment was 60 Gy, while the 
second treatment was 40-50 Gy. During follow-up, patients 
were evaluated at regular intervals both in taking drugs and 
corticosteroids for the performance status. Radiological 
response was evaluated by examining all available imaging 
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modalities, namely CT and MRI. Potential prognostic factors 
in survival were evaluated in the univariate analysis that 
multivariate analysis.  
 
Results: An objective clinical response (ie clinical 
improvement) was observed in 24% of patients. Of the 
evaluable patients, almost one third showed a complete 
radiological response (8%) or partial (22%). The median 
overall survival (OS) and progression-free survival (PFS) after 
retreatment were 10.9 and 8.6 months, respectively. By 
multivariate analysis, we have identified four independent 
prognostic factors for survival: (1), the first perfomance 
status of reprocessing (P = 0.002), (2), the duration of the 
interval between treatments (P 0.008) (three), histology of 
the tumor and (4), the response to initial treatment (P 
values, 0.04). The median survival for patients with 
perfomance status = 0-1 and <2 was of 14.0 and 7.4 months, 
respectively. Patients with oligodendrogliomas showed a 
median OS of 27.5 months while patients with astrocytoma 
had a median OS of 6.9 months after retreatment. There 
were no long-term complications of reprocessing. Quality of 
life after reprocessing and to clinical progression, however, 
was good: all patients remained able to ambulate 
independently and were able to take care of itself. 
 
Conclusion: Re-irradiation in selected patients with relapsed 
brain tumors seems feasible option. 
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Purpose or Objective: Whole brain radiotherapy is the 
standard treatment after resection of brain metastases 
however due to its neurotoxicity some other treatments such 
as stereotactic radiotherapy are under investigation. Our 
purpose is to evaluate the acute toxicity and efficacy of 
postoperative hypofractionated stereotactic radiotherapy to 
the resection cavity in brain metastasis. 
 
Material and Methods: From october 2011 to september 
2015, we treated and analyzed 20 patients diagnosed with 
intracranial metastasis who were treated by resection 
followed by postoperative hypofractonated stereotactic 
radiotherapy. All treatment decisions were based on a 
multidisciplinary approach, all patients signed consent form 
before treatment. In all cases countouring was based on MRI 
and CT fused images, and three different fractionation 
schemes were used : 7 x5 Gy (n=10), 5x6Gy(n=7) and 10x4Gy 
(n=3). Treatment has been performed using the Novalis 
ExacTrac image guided system which consists of a non 
invasive frame-based mask system that allows us to perform 
stereotactic treatments. Treatment plan was performed on 
Iplan-net (v. 4.1) with either multiple non coplanar 
conformal beams or dynamic conformal arcs, using 
3Dconformal radiation therapy or IMRT if it was needed. On 
treatment room the Novalis IGRT is based on two X-ray 
orthogonal images that fuse bone structures with DRR 
reconstructed from CT simulation scan. A Robotic 6D coach 
corrects with submillimeter accuracy translational both and 
rotational errors before treatment.  
 
Results: The median age was 57 years. Seven patients were 
male and 13 female. The most frecuent primary tumor was 
lung in 65%, followed by breast in 25%, and ovary and 
hepatocarcinoma in 5%. All the patients received treatment 
with desxametasone during the treatment and maintained it 
for at least two weeks after the treatment completion. 85% 
of patients remained asymptomatic during treatment. 15% 
had grade I toxicity. Local control was achieved in 85% of 
patients with a median follow up of 13 months. Intracranial 
median free survival was 11,9 months. Median survival time 
was 12 months (range 1- 34months). 30% had new brain 
metastases who were treated with whole-brain radiation 
therapy or radiosurgery.  
 
Conclusion: Stereotactic hypofractionated radiotherapy after 
resection brain metastasis seems feasible and well tolerated. 
No significant toxicity was observed. Whole brain 
radiotherapy can be reserved in cases of progression. 
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Purpose or Objective: Medulloblastoma and central nervous 
system PNET are rare primary brain tumors in adults. The 
role of chemotherapy as a part of standard treatment in 
adult patients is not defined. We aimed to evaluate the 
toxicity and early results of combined treatment: surgery, 
multiagent chemotherapy followed by craniospinal irradiation 
in adult patient. 
 
Material and Methods: From January 2011 to December 
2014, 13 adult patients:6 women and 7 men, with 
medulloblastoma or PNET were treated. Median age was 30,4 
years (20,8-46,7). All patients underwent surgery. There 
were five PNET and eight medulloblastomas, including 
desmoplastic variant in 2 pts, anaplastic in 1 pt, nodularis in 
2 pts and the no specific type in remaining. Neuraxis MRI 
performed after surgery showed active tumor and spinal 
metastases in three pts, tumor in operated site in 5 and no 
signs of disease in 5 pts. There were 6 standard and 7 high 
risk patients. All patients were treated with multiagent 
chemotherapy including cisplatin, cyclophosphamide, 
etoposide and vincristine and received G-CSF as a primary 
prevention of febrile neutropenia. After chemotherapy the 
craniospinal irradiation was performed using conformal 
radiotherapy (8 pts) or tomotherapy (5 pts) with the mean 
dose 32,7 Gy (14,4-36 Gy) to the craniospinal axis and mean 
boost dose of 18,8Gy (18-23,4 Gy) to the primary tumor 
location. MRIs were performed after treatment to monitor 
response. All patients completed the whole protocol. 
 
Results: Ten patients received 2 courses, 2 patients 3 courses 
and one patient received only one course of chemotherapy. 
Chemotherapy was given on time. The hematological toxicity 
of chemotherapy was: neutropenia WHO IV in 2 and WHO III 
in 4 pts after the first course and WHO IV in 4 and WHO III in 
3 pts after the second course of chemotherapy. There was no 
febrile neutropenia. Radiological complete and partial 
response were recorded in 2 and 4 pts respectively in those 
with previous active disease. Two patients progressed while 
waiting for radiotherapy. Mean time of radiotherapy was 1,6 
mo. During radiotherapy hematological toxicity was 
observed: leucopenia – WHO II in 5 pts that started in second 
week of irradiation and WHO III in 2 pts in the third and forth 
week, thrombocytopenia - WHO I in 5 pts, WHO II in 3 pts and 
WHO III in one. Five patients required treatment 
interruptions with median duration of 12 days. Median overall 
treatment time was 6,4 mo. Median follow up was 17,9 mo. 
Six patients relapsed after median time of 13,1 mo, four of 
them locally and two disseminated via cerebral fluid. Five 
patients died in spite of salvage treatment. Median time of 
DFS and OS were 13,3 mo and 17,9 mo respectively. One and 
2 year OS and DFS are 92% and 45% and 68% and 42% 
respectively.  
